Xenetic Biosciences, Inc.
XBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 74.1% | -0.6% | -8.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -50.9% | -122.8% | -158.9% | -169.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -49.7% | -116.7% | -152.2% | -162.5% |
| EPS Diluted | -0.33 | -0.45 | -0.59 | -0.68 |
| % Growth | 26.7% | 23.7% | 13.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |